We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

32 hedge funds and large institutions have $51M invested in Xilio Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more capital inflows, than outflows

Capital inflows: $564K | Capital outflows: $107K

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

14% more funds holding

Funds holding: 28 → 32 (+4)

0.53% more ownership

Funds ownership: 57.98% → 58.51% (+0.53%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
32
Holders Change
+4
Holders Change %
+14.29%
% of All Funds
0.51%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
4
Increased
5
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Rock Springs Capital Management
Rock Springs Capital Management
Maryland
+$244K
2
Citadel Advisors
Citadel Advisors
Florida
+$225K
3
Morgan Stanley
Morgan Stanley
New York
+$15.5K
4
Northern Trust
Northern Trust
Illinois
+$12.6K
5
BlackRock
BlackRock
New York
+$4.92K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$57.4K
2
Millennium Management
Millennium Management
New York
-$31.8K
3
Bank of America
Bank of America
North Carolina
-$18.2K

XLO Hedge Fund Activity: Q1 2023 in Review

32 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2023, worth a combined $51M — up 19% from $42.8M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new XLO positions and 0 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Rock Springs Capital Management, adding an estimated $244K. The largest seller was Renaissance Technologies, cutting an estimated $57.4K.

  • 32 institutional investors held Xilio Therapeutics (XLO) as of Q1 2023, up from 28 in Q4 2022.
  • Funds reported $51M of Xilio Therapeutics stock for Q1 2023, up 19% quarter-over-quarter.
  • 4 funds opened new Xilio Therapeutics positions in Q1 2023 and 0 closed out, a net change of +4 holders.
  • The largest Xilio Therapeutics buyer in Q1 2023 was Rock Springs Capital Management, an estimated $244K added.
  • The largest Xilio Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $57.4K sold.

Based on aggregated 13F filings for Q1 2023.